Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

Eltrombopag is a thrombopoietin receptor (MPL) agonist approved for the treatment of primary immune thrombocytopenia (ITP). Recent evidence shows that some patients may sustain platelet counts following eltrombopag discontinuation. The systemic immunomodulatory response that resolves ITP in some pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lozano, Maria L., Segú-Vergés, Cristina, Coma, Mireia, Álvarez-Roman, María T., González-Porras, José R., Gutiérrez, Laura, Valcárcel, David, Butta, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269123/
https://www.ncbi.nlm.nih.gov/pubmed/34199099
http://dx.doi.org/10.3390/ijms22136907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269123/
https://www.ncbi.nlm.nih.gov/pubmed/34199099
http://dx.doi.org/10.3390/ijms22136907

Ejemplares similares